Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 10/20 | 0.55 |
| ▸ | PPARG | P37231 | 9/20 | 0.55 |
| ▸ | PPARD | Q03181 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 4/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22692661 | 0.91 | CXCR3 (0.49) | PPARAPPARGPPARDALDH1A1TSHR | |
| SCHEMBL7759498 | 0.87 | PPARA (0.52) | PPARAPPARGPPARDALDH1A1TSHR | |
| SCHEMBL5970314 | 0.84 | TDP1 (0.52) | PPARAPPARGPPARDALDH1A1TSHR | |
| SCHEMBL8239220 | 0.84 | ALDH1A1 (0.57) | PPARAPPARGPPARDALDH1A1TSHR | |
| SCHEMBL346337 | 0.84 | ALDH1A1 (0.57) | PPARAPPARGPPARDALDH1A1TSHR | |
| SCHEMBL7911817 | 0.83 | FOLH1 (0.41) | — | |
| SCHEMBL26528173 | 0.83 | CXCR3 (0.49) | PPARAPPARGPPARDALDH1A1TSHR | |
| SCHEMBL18972953 | 0.83 | JAK3 (0.49) | PPARAPPARGPPARDALDH1A1TSHR | |
| SCHEMBL16473048 | 0.82 | PPARA (0.57) | PPARAPPARGPPARDALDH1A1TSHR | |
| SCHEMBL16248664 | 0.82 | JAK3 (0.71) | PPARAPPARGPPARDALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357776-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11732265-B2 | Compositions and methods for modulating complement factor B expression | IONIS PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| EP-4219718-A2 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230057718-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| US-20220324900-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2022-10-13 | — | — | US | disclosed |
| US-20210395734-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-20210277401-A1 | Compositions and Methods for Modulating PKK Expression | IONIS PHARMACEUTICALS, INC. (US) | 2021-09-09 | — | — | US | disclosed |
| EP-3862362-A2 | CONJUGATES OF MODIFIED ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR MODULATING PKK EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3845547-A1 | GALNAC3 CONJUGATED MODIFIED OLIGONUCLEOTIDE FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| US-9957504-B2 | Compositions and methods for modulating apolipoprotein (a) expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957292-B2 | Compositions and methods for modulating angiopoietin-like 3 expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9943604-B2 | Targeted therapeutic nucleosides and their use | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9932580-B2 | Compositions and methods for modulating HBV expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932581-B2 | Compositions and methods for modulating apolipoprotein C-III expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20180044676-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2018-02-15 | — | — | US | disclosed |
| US-9714421-B2 | Compositions and methods | IONIS PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170183661-A1 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170166899-A1 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170159055-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277401-A1 | Compositions and Methods for Modulating PKK Expression | GCKR, PKM, PKLR | PPARA 2574/4885PPARG 2459/4885PPARD 2734/4885 |
| US-20220324900-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | TEK, PLIN3, FABP3 | PPARA 782/4885PPARG 412/4885PPARD 1478/4885 |
| US-20180044676-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | TTR, GALNT1, GALNT3 | PPARA 2357/4885PPARG 1535/4885PPARD 2666/4885 |
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | TTR, GALNT1, GALNT3 | PPARA 2357/4885PPARG 1535/4885PPARD 2666/4885 |
| US-20210395734-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | APOB, APOL1, LDLR | PPARA 831/4885PPARG 655/4885PPARD 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.